Parkinson’s Disease By Nik Sanyal.

Slides:



Advertisements
Similar presentations
Pharmacological Management of Parkinson’s Disease
Advertisements

Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
Linda Pituch, Patient Services Manager, Parkinson’s Disease Foundation
Evaluation of Movement Disorders
Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
An Overview of Conventional and Experimental Treatments
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Idiopathic parkinson’s disease (IPD)
PARKINSON’S DISEASE By Rachel Cheong. WHAT IS PARKINSON’S DISEASE?  Refers to Idiopathic/ Primary Parkinson’s Disease  Parkinsonism of unknown aetiology.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Initial Diagnosis and Management of Parkinson’s Disease
Harald Bjorndalen Adapted from lecture by Dr Zoe Campbell (Medical SpR)
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
931-4 Convergence Insufficiency. History A 73-year old man with known PD for 10 years, complained of horizontal double vision for 18 months. He could.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Parkinson ’ s A Review and Practical Guide to a Common and Complex Disease.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Parkinson’s Disease. Definition Parkinson's disease (PD) is an idiopathic, slowly progressive, neurodegenerative disorder whereby two or more of the following.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Parkinson’s Disease superKAT :).
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Movement Disorders K. Zárubová. Movement disorders MD - abnornal involuntary movements dysfunction of basal ganglia (anatomically) dysfunction of extrapyramidal.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
PARKINSON’S DISEASE By: AARUSHI JAIN AMRUTA KAMBLE ANNETT MARY JACOB AVANTI DEO M.Sc. PRIST (09-11)
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
A neurology primer. Idiopathic Parkinson Disease (also referred to as primary or classical Parkinson disease)  is a progressive neurodegenerative disorder.
second most common neurodegenerative disorder progressive loss of muscle control trembling of the limbs and head while at rest stiffness, slowness, and.
By Katelyn Chaimson and Sean Guyot
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Pathogenesis and pathology of parkinsonism
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
A Primer for Clinicians and Administrators
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinson Disease Parkinson disease is an idiopathic, slowly progressive, degenerative disorder characterized by resting tremor, stiffness (rigidity),
MOVEMENT DISORDERS.
Drugs for Parkinson’s Disease
Parkinson's disease KRZYSZTOF NICPOŃ.
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Atypical Parkinsonian Syndromes
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Pharmacological Management of Parkinson’s Disease
Neurodegenerative diseases
Parkinson’s Disease Definitions Disease features Pathology
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

Parkinson’s Disease By Nik Sanyal

This = movement disorder caused by degeneration of dopamine pathways in substantia nigra Characterised by: TREMOR RIGIDITY BRADYKINESIA +/- postural instability

Epidemiology + Risk Factors Peak age of onset = 55-65 Men > Women 2nd most common neurodegenerative disease after Alzheimer’s Risk factors: Age Gender Spring birth Exposure to pesticides e.g. paraquat or Agent Orange

Pathogenesis Most cases = idiopathic PD. Leading to a progressive degeneration + development of Lewy bodies in substantia nigra. Other pathways – mesocortical, mesolimbic + tubero-hypophyseal Genetics (lead to early onset): mutations in c’some 6 = AR PD Alpha synuclein mutation Parkin gene Dopamine has a role in disinhibition of motor activity hence why reduced levels leads to dyskinesia.

Pathophysiology Cell death in substantia nigra (particularly pars compacta) leads to reduced dopamine secreting cells. Dopamine acts to facilitate release of inhibition and as such in PD there is greater exertion required to initiate a movement as there is less release of inhibition.

Clinical features Resting tremor = usually unilateral before it becomes generalised. It is 4-6 Hz pill-rolling. Typically absent during activity. Rigidity = lead pipe. Cog-wheeling occurs when lead pipe rigidity is broken up by tremor. Bradykinesia = festinant gait (slow to start + small shuffling steps + difficult turns) Has diminished arm swing = leads to recurrent falls. You also get reduction in amplitude of repetitive movements.

Other features Progressive decline over years Mask-like face Impaired swallowing – drooling, choking on food Cognitive decline = depression + dementia Quiet voice progressing to dysarthria Micrographia (small + spidery writing)

DDx Wilson’s Lewy Body dementia: get visual hallucinations CJD: Dementia + myoclonic jerking Parkinson’s plus Huntington’s disease Drug-induced PD Antipsychotics (APAT side effects: acute dystonia, parkinsonism, akathisia, tardive dyskinesia) Lithium Benign essential tremor Rarely at rest, worse on movement Family hx

NICE criteria for Dx Exclude other causes Bradykinesia + at least 1 of: Rigidity 4-6Hz resting tremor Postural instability Supportive criteria: Unilateral Progressive nature Asymmetry before bilateral Response to L-Dopa

Investigations Typically a clinical diagnosis Use: Bedside: BP lying + standing, urine dip Bloods: Genetic testing for Huntington’s or caeruloplasmin for Wilson’s Imaging: CT/MRI Fail to respond to L-Dopa Can visualise structural defects Special tests: DAT scan can differentiate between drug-induced + PD.

Conservative management Advice + explanation, consider non-physical problems (depression, poor sleep, dementia). Limited time frame for meds so start when really needed + started by neurologist! MDT: specialist nurses, OT, SALT, psychiatrist, GP, neurologist, dietician Inform DVLA REHAB

Medical management Drugs alter the natural progression – they just improve symptoms. Levodopa Is the most effective drug. It crosses the BBB and enters the nigrostriatal neurones and is converted to dopamine. Give with dopa-decarboxylase inhibitor e.g. carbidopa to inhibit peripheral metabolism. S/E = N+V, confusion, on-off phenomena, wearing off + dyskinesia, hallucination

Dopamine agonists e.g. Pramipexole = good for motor sx 1st line in younger patients MAO-B inhibitors = selegiline = block dopamine breakdown. Good for motor sx. COMT inhibitors = entacapone = inhibits peripheral break down. S/E = hepatotoxic, N+V, confusion. Amantadine: can be used as monotherapy in early PD but has poor evidence base. Enhances dopamine release. Apomorphine can reduce off periods given as s/c injection. S/E confusion + hallucinations

Surgical Deep brain stimulation Pallidotomy involves surgical destruction of the globus pallidus to control dyskinesia.

Complications Infection Aspiration pneumonia Bed sores Poor nutrition Falls PD dementia

Prognosis Slowly progressive Mean duration 15 years Variable severity Earlier age of onset = poorer prognosis Death usually from complications e.g. pneumonia.

Parkinson’s plus syndromes Disorders with parkinsonism + additional features + specific pathology. Vascular dementia Orthotic hypotension = multi-system atrophy gives insomnia, somnolence, restless legs, hallucinations. Use fludrocortisone for BP Dementia + vertical gaze palsy= progressive supra-nuclear palsy Kayser-Fleischer rings = Wilson’s Apraxic gait – communicating hydrocephalus

Good luck!  Parkinson’s notes Extrapyramidal exam Gait http://www.patient.co.uk/doctor/parkinsonism-and-parkinsons-disease Extrapyramidal exam http://youtu.be/6PDxANv_ME8 Gait http://youtu.be/7SyTpEdhBLw